Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies.

doi:10.1038/s41416-019-0696-y

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies.

British journal of cancer - 1 Mar 2020

Ice Ryan J, Chen Michelle, Sidorov Max, Le Ho Tam, Woo Rinette W L, Rodriguez-Brotons Aida, Luu Tri, Jian Damon, Kim Kevin B, Leong Stanley P, Kim HanKyul, Kim Angela, Stone Des, Nazarian Ari, Oh Alyssia, Tranah Gregory J, Nosrati Mehdi, de Semir David, Dar Altaf A, Chang Stephen, Desprez Pierre-Yves, Kashani-Sabet Mohammed, Soroceanu Liliana, McAllister Sean D

Abstract excerpt

BACKGROUND: Patient-derived xenograft (PDX) mouse tumour models can predict response to therapy in patients. Predictions made from PDX cultures (PDXC) would allow for more rapid and comprehensive evaluation of potential treatment options for patients, including drug combinations. METHODS: We developed a PDX library of BRAF-mutant metastatic melanoma, and a high-throughput drug-screening (HTDS) platform utilising...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to MAP Kinase Kinase Kinases

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Random Allocation

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 31857724
DOI: 10.1038/s41416-019-0696-y
PMCID: PMC7054294

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies.PMID 31857724Read ↗

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of MelanomaSemantic proximity Read ↗

An in vivo avian model of human melanoma to perform rapid and robust preclinical studies.Semantic proximity Read ↗

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.Semantic proximity Read ↗

Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.Semantic proximity Read ↗

Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures.Semantic proximity Read ↗

An <i>in vivo</i> avian model of human melanoma to perform rapid and robust preclinical studiesSemantic proximity Read ↗

Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation.Semantic proximity Read ↗

Uveal Melanoma zebrafish xenograft models illustrate the mutation status-dependent effect of compound synergism or antagonismSemantic proximity Read ↗

Uveal Melanoma Zebrafish Xenograft Models Illustrate the Mutation Status-Dependent Effect of Compound Synergism or Antagonism.Semantic proximity Read ↗

Single-cell genomics analysis reveals complex genetic interactions in an in vivo model of acquired BRAF inhibitor resistance.Semantic proximity Read ↗

Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and AnalysisSemantic proximity Read ↗

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.